| Paula Grace Smith, LICSW | |
|
92 Friendly Rd, Cranston, RI 02910-1218 | |
| (401) 743-0093 | |
| Not Available |
| Full Name | Paula Grace Smith |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 92 Friendly Rd, Cranston, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427304302 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | ISW01043 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Paula Grace Smith, LICSW 92 Friendly Rd, Cranston, RI 02910-1218 Ph: (401) 743-0093 | Paula Grace Smith, LICSW 92 Friendly Rd, Cranston, RI 02910-1218 Ph: (401) 743-0093 |
News Archive
Dr. Paul Fidel, the Carl Baldridge Professor and Associate Dean for Research at LSU Health Sciences Center New Orleans' School of Dentistry, is the lead principal investigator of a $2.76 million grant from the National Institute of Dental and Craniofacial Research over five years to study how HIV and antiretroviral therapy may change communities of bacteria in the mouth and what effects those changes may have on oral infections in HIV disease.
Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in on this new target are underway.
Pfizer said today that Eraxis (anidulafungin) has been approved by the U.S. Food and Drug Administration to treat candidemia, a potentially life-threatening bloodstream infection. Candidemia is the most deadly of the common hospital-acquired bloodstream infections, with a mortality rate of approximately 40 percent.
AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.
› Verified 5 days ago
Bianca Samantha Ogando, MSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 989 Reservoir Ave, Cranston, RI 02910 Phone: 401-422-9051 | |
Jessica Lynn Mowry, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 75 Sockanosset Cross Rd Ste 206, Cranston, RI 02920 Phone: 401-477-4224 | |
Sarah Elizabeth Carter, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1090 Cranston St, Cranston, RI 02920 Phone: 401-781-3990 | |
Ms. Judith Payne St. Angelo, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 135 Norwood Ave, Cranston, RI 02905 Phone: 401-784-3530 Fax: 401-784-3549 | |
Marianne Raimondo, PH.D LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 105 Sockanosset Cross Rd Ste 314, Cranston, RI 02920 Phone: 401-533-4110 | |
Hannah J Schilke, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1471 Elmwood Ave, Cranston, RI 02910 Phone: 000-000-0000 | |
Ms. Jane A Vieira-iemma, MSW LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 75 Sockanosset Cross Rd, Suite 208, Cranston, RI 02920 Phone: 401-862-6031 |